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Mechanism-basedToxicology
in CancerRiskAssessment
"A mechanism is whatever someone else is
working on ata levellowerthan Iam. "
-Anonymous toxicologist
Cancer is a set of diseases characterized by
uncontrolled cell growth. It is thought to be
a complex process involving multiple steps,
any ofwhich may be initiated, altered, and
otherwise affected by exposure to chemical
carcinogens in the environment. Although
an understanding of the process remains
incomplete, recent gains in the knowledge
ofthe mechanisms ofaction ofcarcinogens
both in experimental animals and humans
may help refine current risk assessment
methodology for identifying and quantify-
ing cancer risks associated with chemical
exposure.
For regulatory agencies such as the EPA,
the FDA, and the Occupational Safety and
Health Administration (OSHA), a certain
urgency exists to improve cancer risk assess-
ment. Along with continued concern from
the public about the safety of environmen-
tal chemicals and tremendous pressure from
industry to provide more solid scientific
rationales for specific regulatory decisions,
there are the numbers: of the 70,000 sub-
stances in commerce, adequate toxicological
data are available for only 10-20%. And of
the 50 top-production chemicals in the
United States (which total nearly 700 bil-
lion pounds per year), more than two-thirds
have yet to be evaluated for carcinogenicity
in animals.
These pressures, ofcourse, also have an
impact on that portion of the scientific
community charged with providing public
policy makers with the most complete
information on the environmental compo-
nents ofhuman disease and on the biologi-
cal mechanisms by which these diseases
occur. In terms of cancer risk assessment,
the problem is compounded by time and
money. The conventional 2-year rodent
bioassay, which typically forms the basis of
cancer risk assessment, costs between $2
and $4 million and requires 4-6 years to
complete. "At present, with current re-
sources, we can test only 10 to 15 chemicals
by this approach each year," says George
Lucier, director of the Environmental
Toxicology Program at the NIEHS.
Another important issue is uncertainty.
Cancer risk assessment ofchemical exposure
relies heavily on tumor data from animal
carcinogenicity bioassays conducted at high
doses. Positive bioassay findings are fre-
quently followed by mathematical extrapo-
lation to the much lower exposure levels
anticipated for environmental exposures of
humans.
Along the way to a carcinogenicity
assessment, and in the absence ofknowlege
that demonstrates otherwise, certain conser-
vative inferences or "defaults" are assumed
such as the conservation of biological
processes among species, the inference of
similar susceptibility between animals and
humans; the assumption that susceptibilities
within a population do not differ by age,
gender, or genetics; and the assumption of
low-dose linearity-that chemicals act like
radiation at low doses to induce cancer, and
that a single mutational change can result in
adverse effects down the road. And so,
when actual or more accurate data are either
unavailable, incomplete, or inadequate, use
ofdefaults add their own varying degrees of
uncertainty regarding the
carcinogenicity of a particu-
lar chemical. Thus, says
Lucier, regulatory agencies
are often forced to make
decisions on chemicals and
safe exposure levels without
an adequate science base.
Modes ofAction
"We are charged with
decreased use of animals,
charged with developing
alternatives for screening chemicals more
rapidly and to set priorities for further test-
ing," says J. Carl Barrett, head ofNIEHS's
Environmental Carcinogenesis Program.
"Mechanism-based toxicology presents one
type of alternative." According to Barrett,
mechanism-based toxicology (MBT)
involves "the use of knowledge of mecha-
nisms both ofdisease process and ofchemi-
cal effects to better predict the toxicological
potential of chemicals, to estimate risk at
low doses, to extrapolate between species,
and to quantitate interindividual differ-
ences in response.
Support for the use ofMBT data can be
found in EPA's proposed revisions to its
Guidelinesfor Carcinogen Risk Assessment
(August 1994). In its draft document, the
agency leaves room for inclusion of more
biologically based data as a means ofreduc-
ing the uncertainty associated with extrapo-
lation of risk. While acknowledging that
the mechanisms by which any chemical
causes cancer may never be completely
detailed, scientists involved in formulating
the proposed EPA revisions generally
agreed that this should not preclude the use
of scientifically supportable "mode of
action data" in the risk assessment process.
Barrett points to three fundamental
modes or mechanisms of action by which
chemically induced cancer can arise: herita-
ble mutations in critical target genes, herita-
ble epigenetic changes in
cellular phenotype, and
clonal evolution or expan-
sion of cells influencing
the probability of subse-
quent mutations occurring
E _ either spontaneously or
through exogenous expo-
sure. An example, explains
_ Barrett, is diethylstilbestrol
(DES) exposure in utero.
Developmentally timed
exposure of this synthetic
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estrogenic compound can change the tissue
differentiation pattern throughout the life-
time. "Ifyou give DES during the first five
days ofdevelopment, adult animals have a
totally different pattern, adifferent differenti-
ation, than nonexposed animals. So there are
critical periods in development where expo-
sures can change the progression ofgrowth
and control ofcells that may lead to the can-
cer process," says Barrett. "These are not
mutually exclusive. A chemical can exert
multiple mechanisms ormodes ofaction."
Advantages
As Barrett points out, advantages of MBT
are that it allows many more substances or
chemicals to be tested for biological activi-
ties, provides an alternative to the use of
animals, and provides more efficient design
of toxicology studies. "For example, ifyou
know a chemical exerts an impact on
cell-cell communication, then you might
look at its impact on cancer or noncancer
endpoints," Barrett says.
MBT may also be applied to testing the
validity of certain default assumptions; for
example, the conservation of biological
processes, including mechanisms. "If you
look at how the steroid hormone receptor
functions, it doesn't matter ifit's a yeast or
a man; it functions the same way," says tox-
icologist Linda Birnbaum of EPA's Health
Effects Research Laboratory. "And I think if
you understand how an effect or part ofan
effect is brought about, you can look at
whether those mechanisms are working in
man as well as in experimental animals."
Birnbaum adds: "Sometimes there are much
shorter assays that demonstrate carcinogenic
potential. Maybe by applying mechanistic
approaches one can understand under what
circumstances that potential is realized."
In the initial stages of risk assessment,
MBT can be used to more rapidly screen
chemicals and to set priorities for further
studies. In terms ofmutational activity, for
example, current knowledge ofcritical sup-
pressor genes, such as p53, might be
exploited to understand the carcinogenic
mechanisms of specific chemicals. Another
example is receptor-mediated pathobiology,
the knowledge that some chemicals, such as
dioxin and estrogens, seem to cause diseases
by interacting or binding with specific
receptors. Molecular proteins such as the
Ah receptor may help predict the toxicolog-
ical impact ofother chemicals. And in terms
of structure-activity relationships (SAR),
the knowledge that certain types of chemi-
cals do or do not share structural or biologi-
cal properties associated with mechanisms
critical to carcinogenesis can help strength-
en or weaken concern about an agent's car-
cinogenicity. Mutational and SAR analysis
as well as knowledge of receptor-mediated
activity may also offer a rationale for reason-
ably assuming hazard and may
preclude costly and time-con-
sumingbioassays.
Another use of MBT in
cancer risk assessment is in
determining dose-response
relationships for chemical 's
effects at low doses. Dose-
response assessment refers to
the process of estimating the /
relationship of dose of a sub- i
stance to degree ofeffect. MBT
can be used to explore and
identify mutational activity, _l^_
receptor-mediated effects, phar- Michael Gall
macodynamics, and pharmaco- take a hard
kinetics. mediated me
Michael Gallo, director of
the NIEHS Center of Excellence at New
Jersey's Robert Wood Johnson Medical
School, says he sees agreater emphasis on the
role played by receptor-mediated mecha-
nisms involved in carcinogenesis, particularly
the hormonal component. "We now know
that the receptor-mediated mechanisms may
be the classic of all cancer promoters. The
receptors we're studying are involved in
growth regulation-the Ah receptor, the
estrogen receptor, the epidermal growth fac-
tor receptor, the thyroid hormone receptor.
We have to take a hard look at them." Thus,
it follows that dose-response assessment for
an effect other than mutagenesis or tumor
incidence may be useful for assessing poten-
tial environmental carcinogens. If carcino-
genic effects are secondary to precursor mole-
cular effects, such as disruption ofhormonal
activity, such precursor events may be more
relevant than tumor incidence for risk assess-
lo-
look
char
ment. Gallo says amajor area of
_ concern today is the role played
" by hormonal or endocrine dis-
'ruptors in the environment. "If
we can show that disruption or
1t modification ofa hormone is in
fact an effector for cancer, then
there are secondary or tertiary
mechanisms involved."
Measurement of biochemical
/ _ or molecular events following
chemical exposure has also
sparked considerable interest in
Or"W"', the use of biomarkers in risk
We have to assessment. MBT may be use-
at receptor- ful in evaluating the quantita-
isms. tive and qualitative relation-
ships of these markers to toxic
effects. At the recent NTP Workshop on
Mechanism-based Toxicology in Cancer
Risk Assessment, a dose-response work
group considered thevalue ofbiomarkers for
risk assessment. They said some biomarkers
may help determine exposure to a carcino-
gen and its effect. For example, biomarkers
reflect gene mutations directly related to car-
cinogenesis or to alterations in gene expres-
sion. Comparisons of animal model and
human molecular biomarkers wereviewed as
potentially useful for establishing inter-
species dosimetryand susceptibility.
Another NTP workshop subgroup con-
cluded that it would be useful and appropri-
ate to apply mechanistic information to
assessing the relevance ofthe rodent bioassay
for humans. Participants pointed out that
the collection of relevant mechanistic data
can either support the interspecies extrapola-
tion default or could otherwise provide a
Meeting on mechanisms. A recent meeting on mechanism-based toxicology broughttogether leaders in
environmental health. (leftto right) George Lucier, Lynn Goldman, EPA assistant administratorfor preven-
tion, pesticides and toxic substances, NIEHS Director Kenneth Olden, and J. Carl Barrett.
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rationale for revising it.
They also concluded that
mechanistic information
could be used prospectively
in the design of chronic
rodent bioassays as an aid in
selecting route of adminis-
tration, dosing, species
selection, and endpoints. If,
for example, the data indi-
cated compound-induced
cell proliferation or cytotox-
icity, this would provide a
basis for monitoring those Brian Hardin-S
endpoints in the bioassay. can beusedtode
The workshop subgroup
saw biomarkers of suscepti-
bility, such as those indicative of polymor-
phisms of metabolism, detoxication, and
DNA repair, as presenting "a promising
opportunity for interindividual and inter-
species extrapolation," as well as having pos-
sible utility for evaluating age and/or sex-
related differences in human susceptibility.
What is Enough?
Mechanism-based toxicology appears to
offer tremendous potential for cancer risk
assessment, but how much evidence is
enough? As Barrett points out, in spite of
MBT's potential, what is needed is a com-
fort level with some sort of minimum data
for risk assessment decisions. Toxicologist
Ellen Silbergeld of the University of
Maryland, agrees. "It is important to come
up with some understanding as to what is
the minimum amount of data that would
allow both scientists and regulators to pro-
ceed together with some degree of confi-
dence, with some ability to communicate to
the public, the nature and extent of risk."
She cautions that unless some limits are set,
"We are in danger of being attracted into
the very gray area between risk assessment-
related research and basic biology, which is
the endless quest for knowledge but may
not be exactly consonant with the needs as
well as the resources to make informed and
practical decisions. I think ofan analogy to
clinical medicine, and I am aware now that
as I teach medical students that they don't
have to understand everything about molec-
ular biology and disease process in order to
make a clinical decision. It seems to me
we've been remiss in establishing that same
type of strategic outlook in how we bring
science into the regulatoryprocess."
For Brian Hardin, senior scientist in the
Office ofthe Director at NIOSH, the issue
can be viewed from another perspective.
"Pursuit of more and better scientific data
can be used very effectively by forces whose
interests are served by avoiding action, by
,cien
elay
_ ence before some government
z2 intervention is allowed that
would disturb the established
order, perhaps at the expense of
public health. "Whose risk is
being minimized?" he asks.
Hardin, along with other scien-
tists, also expresses concern that
resources gained for mechanistic
research will come at the expense
of whole-animal bioassays and
epidemiologic studies. "Those
sorts of studies provide the most
itific data convincing and most powerful
action. tools we have today for protect-
ing human health. Despite the
faith we all have in mechanistic
work, I predict it will be many, many years
before it is possible to regulate any chemi-
cal in commerce as a carcinogen in the
absence of epidemiologic or animal evi-
dence ofcarcinogenicity," Hardin says.
Birnbaum points out that conventional
long-term bioassays may still be controver-
sial after their completion. She says the use
of short-term MBT studies that are highly
predictive of a compound's likelihood of
carcinogenicity could be
used to support two-year
bioassay findings. "That
in fact could result in
agreement that the com-
pound is a bad actor and
should not be used. In
that sense we would have
done a good job of pro-
tectingthe public health."
Recommended by
Birnbaum and others is a
more iterative and integra-
tive approach to data col- EllenSilbergeld-T
lection for risk assessment to be an understan lection
fr is ases smAt en NT the minimum amot purposes. At the NTP neededforriskasse
workshop, Silbergeld
reminded participants that
the bioassay is an extremely rich source of
information and offers the only lifetime sur-
veillance opportunity of an animal model.
She recommends expanding the bioassay to
provide more mechanistic information as it is
proceeding. "That may allow you to stop at
certain times, evaluate where you are, but at
the same time preserve an established struc-
There
nding
unt
essn
Uses of MBT
* To more rapidly screen chemicals
and set priorites forfurtherstudies
* As a basis for reasonably assuming
hazard (rebuttable presumption)
* To determine quantitative dose-
response relationships
* To understand species, strain, and
individual differences in susceptibility
* For species extrapolations
* For more efficient experimental
design
ture and possibly be more economical overall
because you'll be able to eliminate as you go
along," Silbergeld adds. "I don't think the
problem here is including mechanistic infor-
mation. The problem here is making justifi-
able selection among an enormous array of
potential mechanistic approaches that could
be applied."
Few would argue that increased use of
mechanism-based toxicology should mean
severely diminished use ofthe conventional
bioassay. Rather, MBT should be used in
- addition to current testing strate-
gies, not as a substitute for them,
and study designs should be devel-
oped to provide the information
needed for the best-informed risk
assessments.
Today, several key impediments
exist to the use ofmechanistic data
in risk assessment for cancer: com-
fort among scientists and regulators
with the status quo; constraint by
regulatory legislation; concern with
the implications for making costly
e needs decisions. It has been said that sci-
g about ence needs to evolve to increase its
efndata own confidence in mechanistically
based predictions. For this work to
continue, it is imperative that con-
fidence also be increased among legislators,
regulators, and the public.
Leslie Lang
Leslie Lang is a freelance journalist in Chapel Hill,
North Carolina.
delaying action . . . 'paralysis by analysis'.
He says these forces can make skillful and
plausible appeals for more and better sci-
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